Journal
ALCOHOL-CLINICAL AND EXPERIMENTAL RESEARCH
Volume 39, Issue 2, Pages 300-307Publisher
WILEY
DOI: 10.1111/acer.12619
Keywords
Alcohol; Family History; Memantine; Drinking
Categories
Funding
- National Institute on Alcohol Abuse and Alcoholism Center [P50AA12870, M01RR00125]
- Pfizer, Inc.
- Alkermes
- Lipha Pharmaceuticals
- GlaxoSmithKline
- Forest Laboratories
- Dupont
- OrthoMcNeil
- Bristol-Meyers Squibb
- Sanofi-Aventis
- Mallinckrodt
Ask authors/readers for more resources
BackgroundThe objective of this study was to determine the effects of the N-methyl-d-aspartate (NMDA) receptor antagonist, memantine (0, 20, 40mg/d), upon alcohol drinking and craving in heavy drinkers with or without a family history (FH) of alcoholism, and to explore the modulatory influence of the presence of impulsivity on these outcomes. MethodsNinety-two, nontreatment-seeking, heavy drinkers received memantine or placebo for 8days. On the eighth day, they received a priming dose of alcohol followed by a 3-hour period of alcohol access. ResultsMemantine at a dose of 20mg reduced alcohol craving but did not influence alcohol drinking. No effects of FH were observed. In participants with higher baseline levels of impulsivity, 40mg of memantine reduced alcohol craving but increased alcohol drinking and alcohol-induced stimulation. ConclusionsNMDA receptor signaling may play divergent roles in mediating alcohol cue-induced craving and alcohol drinking in heavy drinkers. The potential efficacy of memantine as monotherapy for alcohol use disorders may be limited by its tendency to disinhibit drinking in some individuals.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available